A 67-year-old woman taking a common hepatitis B medication for many years developed severe bone problems, including weak bones and pain. Doctors discovered the medication was preventing her body from absorbing phosphate, a mineral needed for strong bones. When she stopped taking the drug and received vitamin D and phosphate supplements, her bone pain went away and her blood tests improved. However, her bones remained weaker than normal for her age, suggesting she also had age-related bone loss. This case shows that while stopping a harmful medication can help bones recover, some patients may need additional treatment if they have other risk factors for weak bones.
The Quick Take
- What they studied: How a hepatitis B medication called adefovir dipivoxil damaged one patient’s bones and what happened when the medication was stopped
- Who participated: One 67-year-old woman who had gone through menopause and had been taking adefovir dipivoxil for chronic hepatitis B for a long time
- Key finding: Stopping the medication and adding vitamin D and phosphate supplements fixed the bone disease caused by the drug, but the patient’s bones remained weaker than expected for her age
- What it means for you: If you take adefovir dipivoxil for hepatitis B and develop bone pain or weakness, talk to your doctor immediately. Stopping the medication can help, but you may need additional bone-strengthening treatment, especially if you’re older or have other bone disease risk factors
The Research Details
This is a case report, which means doctors documented what happened to one specific patient over time. The patient was a 67-year-old woman who had been taking adefovir dipivoxil (a medication for chronic hepatitis B) for many years. She came to the hospital complaining of severe bone pain and was found to have multiple stress fractures (small cracks in bones). Doctors ran blood tests and bone density scans to figure out what was wrong.
The doctors discovered that the medication had damaged her kidneys in a way that prevented her body from absorbing and keeping phosphate, an important mineral for bone health. This condition is called Fanconi syndrome, and it led to a bone disease called hypophosphatemic osteomalacia (soft bones caused by low phosphate). The patient then stopped taking adefovir and started taking vitamin D and phosphate supplements. Doctors tracked her progress with blood tests and bone density measurements over time.
Case reports are important because they document unusual or serious side effects that might not show up in regular studies. This case is valuable because it shows a real-world example of how a medication used by many hepatitis B patients can cause serious bone problems. It also demonstrates what happens when the medication is stopped and how long recovery takes. This information helps doctors recognize similar problems in other patients and know what to do about them.
This is a single case report, which means it describes what happened to one patient. While this provides valuable real-world information, it cannot prove that the same thing will happen to everyone taking this medication. The doctors did thorough testing and follow-up, which makes the case well-documented. However, to understand how common this problem is and how often it happens, we would need larger studies with many patients. This case is most useful for alerting doctors to watch for these symptoms in their patients taking adefovir dipivoxil.
What the Results Show
The patient presented with severe bone pain and was found to have multiple stress fractures (small cracks in bones that occur without major injury). Blood tests showed very low phosphate levels and abnormal vitamin D metabolism. Bone density scans showed her bones were much weaker than normal for a woman her age. After stopping adefovir dipivoxil and starting vitamin D and phosphate supplements, her bone pain improved significantly within the follow-up period. Her blood test results returned to normal ranges, indicating that the bone disease caused by the medication had been corrected.
However, when doctors repeated the bone density scans after treatment, they found an important difference: while her bone density did improve compared to when she started treatment, it remained significantly lower than what would be expected for a healthy woman her age. This suggested that she had developed age-related bone loss (osteoporosis) in addition to the medication-induced bone disease. Because of this, doctors started her on additional medications specifically designed to strengthen bones and prevent fractures.
The case demonstrates that the kidney damage from adefovir dipivoxil was reversible—once the medication was stopped, the kidneys’ ability to handle phosphate improved. The patient’s biochemical markers (blood test results) normalized, showing that the body’s mineral balance was restored. The improvement in bone pain was one of the first signs that treatment was working. The case also shows that bone density can improve after removing the harmful medication, but the improvement may not be complete if other factors (like age and menopause) have already weakened the bones.
This case adds to existing medical knowledge about adefovir dipivoxil’s side effects. Doctors have known for some time that this medication can damage kidneys and cause Fanconi syndrome in some patients. However, this case provides detailed documentation of how the bone disease develops, what symptoms appear, and what happens during recovery. It confirms that stopping the medication is important and that vitamin D and phosphate supplements can help. The case also highlights an important point that previous reports may not have emphasized as clearly: even after the medication-induced bone disease is fixed, patients may still have weak bones from other causes and need additional treatment.
This is a report of only one patient, so we cannot know how common this problem is or whether all patients will respond the same way to treatment. The patient was a postmenopausal woman, so the results may not apply to younger patients or men. We don’t know the exact length of time the patient took adefovir dipivoxil before symptoms appeared, or how long the follow-up period was after stopping the medication. The case doesn’t tell us whether other patients taking this medication for hepatitis B have similar problems or whether certain patients are at higher risk. To answer these questions, researchers would need to study many patients taking adefovir dipivoxil over time.
The Bottom Line
If you are taking adefovir dipivoxil for hepatitis B, work closely with your doctor to monitor your bone health. Report any bone pain, weakness, or difficulty walking immediately. Your doctor may recommend periodic blood tests to check phosphate and vitamin D levels, and bone density scans to monitor bone strength. If bone problems develop, stopping the medication (with your doctor’s guidance) combined with vitamin D and phosphate supplements appears to be effective. However, you may also need additional bone-strengthening medications, especially if you are older or have other risk factors for weak bones. The confidence level for these recommendations is moderate, based on this single detailed case and supporting medical knowledge.
This case is most relevant to people taking adefovir dipivoxil for chronic hepatitis B, particularly those who are older, postmenopausal, or have other risk factors for bone disease. Doctors treating hepatitis B patients should be aware of this potential side effect. Family members of patients taking this medication should know the warning signs. People considering adefovir dipivoxil as a treatment option should discuss bone health risks with their doctor. This case is less relevant to people taking other hepatitis B medications or those without hepatitis B, though the general principle that medications can affect bone health applies broadly.
In this case, bone pain improved noticeably after starting vitamin D and phosphate supplements, though the exact timeline isn’t specified. Blood test results normalized relatively quickly after stopping the medication and starting supplements. Bone density improvement took longer—the follow-up scans showed improvement compared to baseline, but this likely took several months to become apparent. Full recovery of bone strength may take 6-12 months or longer, and some patients may need ongoing treatment. If you develop symptoms, improvement should begin within weeks to months of starting appropriate treatment, but complete recovery of bone strength takes longer.
Want to Apply This Research?
- If taking adefovir dipivoxil, track bone-related symptoms weekly: record any bone pain (location and severity on a 1-10 scale), muscle weakness, difficulty walking or climbing stairs, and any falls or injuries. Also note any new medications started or stopped.
- Users taking adefovir dipivoxil should set monthly reminders to schedule check-ins with their doctor about bone health, ensure they’re taking vitamin D and calcium supplements as prescribed, and log any concerning symptoms immediately rather than waiting for a scheduled appointment.
- Establish a long-term tracking system that records: (1) bone pain and mobility changes monthly, (2) medication adherence and any changes to adefovir dipivoxil dosing, (3) supplement intake (vitamin D, phosphate, calcium), (4) scheduled bone density scan results and dates, and (5) blood test results for phosphate and vitamin D levels. Share this log with your healthcare provider at each visit.
This case report describes what happened to one specific patient and should not be interpreted as medical advice. If you are taking adefovir dipivoxil or any other medication for hepatitis B, do not stop taking it without talking to your doctor first. Bone pain, weakness, or other symptoms should be reported to your healthcare provider immediately for proper evaluation. The findings in this case may not apply to all patients. Always consult with your doctor before making any changes to your medication or treatment plan. This information is for educational purposes and is not a substitute for professional medical diagnosis or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.